UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~May~~August 225, 2025

RIGEL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

0-29889		94-3248524
(Commission File No.)		(IRS Employer Identification No.)
611 Gateway Boulevard, Suite 900
611 Gateway Boulevard Suite 900
South San Francisco, CA		94080
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (650) 624-1100

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per share		RIGL		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 52.02. ~~Departure~~Results of ~~Directors~~Operations orand ~~Certain~~Financial ~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Condition.

~~Approval~~On August 5, 2025, Rigel Pharmaceuticals, Inc. (“Rigel”) announced certain financial results for its second quarter ended June 30, 2025. A copy of ~~2018~~Rigel’s ~~Equity~~press ~~Incentive~~release, ~~Plan~~titled “Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update,” is furnished pursuant to Item 2.02 as ~~Amended~~Exhibit 99.1 hereto.

OnThe ~~May 22,~~information ~~2025~~in this report, atincluding the ~~2025~~exhibit ~~Annual~~hereto, ~~Meeting of~~shall ~~Stockholders~~not ~~(the~~be ~~“Annual~~deemed ~~Meeting~~to be “filed”) for purposes of ~~Rigel~~Section ~~Pharmaceuticals, Inc.~~18 (of the ~~“Company”),~~Securities ~~the~~Exchange ~~Company’s~~Act ~~stockholders~~of ~~approved~~1934, ~~the~~as ~~amendment~~amended, or otherwise subject to the ~~Company’s~~liabilities ~~2018~~of ~~Equity~~that ~~Incentive~~section ~~Plan~~or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. (The information contained herein and in the ~~“Amended~~accompanying exhibit shall not be incorporated by reference into any filing ~~2018~~with ~~Plan”),~~the ~~to,~~U.S. ~~among~~Securities ~~other~~and ~~items,~~Exchange ~~add~~Commission anmade ~~additional~~by ~~700~~Rigel,~~000~~ ~~shares~~whether tomade ~~the~~before ~~number~~or ofafter ~~shares~~the ofdate ~~common~~hereof, ~~stock~~regardless ~~authorized~~of ~~for~~any general ~~issuance~~incorporation ~~under~~language ~~the~~in ~~Amended~~such ~~2018 Plan~~filing.

The Amended 2018 Plan previously had been approved, subject to stockholder approval, by the Board of Directors of the Company. The Amended 2018 Plan became effective immediately upon stockholder approval at the Annual Meeting.

Item 9.01.	Financial Statements and Exhibits.

*(d)*	*Exhibits.*

A more detailed summary of the material features of the Amended 2018 Plan is set forth in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 10, 2025 (the “Proxy Statement”). That summary and the foregoing description are qualified in their entirety by reference to the text of the Amended 2018 Plan, which is attached as Appendix A to the Proxy Statement.

Exhibit		Description

99.1		Press Release, dated August 5, 2025, titled “Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update.”
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

~~Item 5.07. Submission of Matters to a Vote of Security Holders.~~SIGNATURES

~~The~~Pursuant ~~following~~to isthe ~~a brief description~~ requirements of ~~each matter voted upon at~~ the ~~Annual~~Securities ~~Meeting,~~Exchange asAct ~~well as the number~~ of ~~votes~~1934, ~~cast for or against each matter and~~ the ~~number~~registrant ofhas ~~abstentions~~duly ~~and~~caused ~~broker non-votes~~this ~~with~~report ~~respect~~ to ~~each~~be ~~matter.~~signed Aon ~~more~~its ~~complete~~behalf ~~description~~by ~~of each matter is set forth in~~ the ~~Proxy~~undersigned ~~Statement~~hereunto duly authorized.

Election of Directors

Dated: August 5, 2025	RIGEL PHARMACEUTICALS, INC.

	By:	/s/ Raymond J. Furey
		Raymond J. Furey
		Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary

Each of the nominees for director, to serve until the Company’s 2028 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified, was elected as follows:

Name of Director	For		Withheld		Abstain		Broker Non-Votes
Kamil Ali-Jackson		10,542,422		227,808		199,277		2,860,105
Jane Wasman		10,380,140		387,223		202,144		2,860,105

Approval of the Amended 2018 Plan

The Company’s stockholders approved the Amended 2018 Plan.

For				Against				Abstain				Broker Non-Votes
	6,856,776				3,591,569				521,162				2,860,105

Say-on-Pay

The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.

For				Against				Abstain				Broker Non-Votes
	9,388,816				993,913				586,778				2,860,105

Ratification of Selection of Ernst & Young

The Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.

For				Against				Abstain				Broker Non-Votes
	12,876,978				877,950				74,684				—

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 23, 2025	RIGEL PHARMACEUTICALS, INC.
	By:	/s/ Raymond J. Furey
		Raymond J. Furey
		Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary

Filing Compare · RIGEL PHARMACEUTICALS INC